VPC-13789

VPC-13789 is a potent, selective, and orally bioavailable antiandrogen. VPC-13789 can be used for the research of castration-resistant prostate cancer (CRPC) therapeutics. VPC-13789 inhibits androgen receptor (AR) transcriptional activity in LNCaP cells (IC50=0.19 μM) [1].

Product Specifications

CAS Number

[2761146-51-2]

UNSPSC

12352005

Target

Androgen Receptor

Type

Reference compound

Related Pathways

Vitamin D Related/Nuclear Receptor

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Cancer; Endocrinology

Assay Protocol

https://www.medchemexpress.com/vpc-13789.html

Solubility

10 mM in DMSO

Smiles

O=C(C1=C2C=CC(C3=CNC4=C3C=C(F)C(F)=C4F)=NC2=CC=C1)NC(C)C

Molecular Formula

C21H16F3N3O

Molecular Weight

383.37

References & Citations

[1]Eric Leblanc , et al. Development of 2- (5,6,7-Trifluoro-1 H-Indol-3-yl) -quinoline-5-carboxamide as a Potent, Selective, and Orally Available Inhibitor of Human Androgen Receptor Targeting Its Binding Function-3 for the Treatment of Castration-Resistant Prostate Cancer. J Med Chem. 2021 Oct 28;64 (20) :14968-14982.